Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1156-1159

  Tsai, Jui Hsiu ^a   Yang, Pinchen ^b   Yen, Ju Yu ^a   Chen, Cheng Chung ^a,c   Yang, Ming Jen ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Tsyr Huey Mental Hospital   (Taiwan)

Author keywords

Catatonia; NMS; Risperidone; Zotepine

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; BROMOCRIPTINE; CREATINE KINASE; CREATININE; DANTROLENE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FENFLURAMINE; FUROSEMIDE; HALOPERIDOL; MUSCLE ENZYME; NEUROLEPTIC AGENT; NITROGEN; OLANZAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SULPIRIDE; UREA; ZOTEPINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CATATONIA; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; HYPERTHERMIA; INTENSIVE CARE UNIT; LEUKOCYTOSIS; MALE; MORTALITY; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; SCHIZOPHRENIA; TACHYCARDIA;

ANTIPSYCHOTIC AGENTS; BLOOD CHEMICAL ANALYSIS; CATATONIA; DIBENZOTHIEPINS; DISEASE PROGRESSION; FEVER; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE; SCHIZOPHRENIA, PARANOID;

EID: 23244463157     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1156     Document Type: Article

References (23)

1. Gelenberg AJ. The catatonic syndrome. Lancet 1976;1: 1339-41.
2. Gelenberg AJ, Manley MR. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 1977;34:947-50.
3. Stoudemire A, Luther JS. Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment. Int J Psychiatr Med 1984;14:57-63.
4. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
5. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.
6. Pearlman C. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986;6:257-73.
7. Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry 1985;20:304-13.
8. Lazarus A, Mann SC, Caroff SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press, 1989.
9. Hatch CD, Lund BC, Perry PJ. Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics. Pharmacotherapy 2001;21:1003-6.
10. Worrel J, Marken R, Beckman S, Ruehter V. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 2000;57:238-55.
11. Prakash A, Lamb HM, Zotepine. CNS Drugs 1998;9:153-75.
12. Noto T, Hashimoto H, Sugae S, et al. Hypothermia caused by antipsychotic drugs in a schizophrenic patient. J Clin Psychiatry 1987;48:77-8.
13. Mieno S, Asada K, Horimoto H, Sasaki S. Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene. Eur J Cardiothorac Surg 2003;24:458-60.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:739-42.
15. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15:365-71.
16. Costa E, Gropetti A, Revuelta A. Action of fenfluramine on monoamine store of rat tissues. Br J Pharmacol 1971;41:57-64.
17. Duhault J, Verdavainne C. Modification du taux de serotonine cérébrale chez rat par les trifluoromethylphenyl-2-ethyl aminopropane (fenfluramine 768S) [in French]. Arch Int Pharmacodyn Ther 1967;170:276-86.
18. Shimomura K, Satoh H, Hirai O, et al. The central anti-serotonin activity of zotepine, a new neuroleptic, in rats. Jpn J Pharmacol 1982;32:405-12.
19. Gill J, Singh H, Nugent K. Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 2003;23:811-15.
20. Sparrow P, Murnaghan D, Kearney P, Hogan J, Sheppard MN. Acute cardiac failure in neuroleptic malignant syndrome. Eur J Heart Fail 2003;5:575-8.
21. Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 1988;22:475-80.
22. Buckley PF, Hvitchinson M. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 1995;58:271-3.
23. Rosebusk PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50:295-8.